Do I need T3?

Kasi Subbiah
4 days ago
8 min read

Updated: 3 days ago

Levothyroxine Not Working? Here's What Science Says About Adding T3

A patient-friendly guide to combination therapy, desiccated thyroid extract and pregnancy

Evidence reviewed: September 2026

Most people with hypothyroidism are treated with levothyroxine, a synthetic form of the thyroid hormone thyroxine (T4). The body normally converts T4 into the more active hormone triiodothyronine (T3).

For most people, that arrangement works well. Some, however, continue to experience tiredness, difficulty concentrating, low mood, weight problems or a general sense that they are not completely well - even when their thyroid-stimulating hormone (TSH) is within the normal range. This raises a reasonable question: would adding T3 (as Liothyronine) help?

The short version: clinical trials have not consistently shown that levothyroxine-plus-liothyronine treatment improves persistent symptoms more than levothyroxine alone. Some individual patients nevertheless report feeling better and prefer combination treatment. T3 is therefore not recommended routinely, but a carefully supervised trial may be reasonable for selected adults after the diagnosis, levothyroxine dose and alternative causes of symptoms have been properly reviewed. 'Not routinely' is not the same as 'never'; it is medicine's less dramatic way of saying, 'Choose carefully and measure what happens.'

Why combination therapy?

T4 has a half-life of approximately seven days, so it provides relatively stable hormone levels. T3, or liothyronine, has a much shorter half-life. Microgram for microgram, T3 is roughly three to four times more potent than T4, which means even a small dose can have a substantial and rapid effect. T4 is the steady long-distance runner; T3 arrives more like a sprinter who has already heard the starting pistol.

For both reasons, T3 is normally prescribed in much smaller doses than T4 and divided into twice-daily doses to reduce sharp peaks and fluctuations. When used, liothyronine is usually added to levothyroxine rather than given by itself. The longer-acting T4 supplies a steady reserve, while the smaller T3 dose supplements the active hormone. This more closely resembles normal thyroid function and reduces the peaks and falls that can occur with short-acting T3 alone.

Liothyronine alone is generally not recommended, except in unusual circumstances such as a confirmed allergy or intolerance to levothyroxine or its ingredients.

Does adding T3 help persistent symptoms?

Clinical trials have not consistently shown combination therapy to improve residual symptoms. At the population level, the evidence has not established a clear advantage over levothyroxine alone. Nevertheless, some individual patients report feeling better on treatment containing T3 and prefer it.

That is why combination treatment is not standard therapy for most patients, but may be considered in carefully selected people under specialist supervision. A thoughtful trial is an experiment with an agreed question and an agreed stopping point - not a lifetime prescription issued because Tuesday felt promising.

Before considering T3

Clinicians should work through the following points before starting combination therapy:

1. Confirm the original diagnosis: There should be clear biochemical evidence that the patient had overt hypothyroidism.

2. Optimise levothyroxine first: The levothyroxine dose should be properly optimised, aiming for a TSH in the 0.3-2.0 mU/L range.

3. Avoid long-term TSH suppression: In some patients, a TSH slightly below the reference range - for example, 0.1-0.3 mU/L - may be acceptable, but it should never be fully suppressed in the long term.

4. Allow enough time: Give optimised levothyroxine treatment three to six months before judging the response.

5. Look for other explanations: Consider anaemia, vitamin deficiencies, sleep problems, obstructive sleep apnoea, menopause, depression, anxiety, coeliac disease, medication effects or another medical condition.

If these criteria are satisfied, a supervised trial of levothyroxine plus liothyronine may be considered after shared decision-making. The trial should be reviewed after an agreed period and continued only if it produces a meaningful improvement in symptoms.

What about desiccated thyroid extract (DTE)?

Desiccated thyroid extract, including products such as Armour Thyroid, is made from dried pig thyroid glands; bovine and ovine preparations have also been available. DTE was the first treatment for hypothyroidism, before synthetic levothyroxine was developed. In the United States it has never been regulated by the FDA, because its use predates the current approval process.

One grain of DTE is usually 60 mg, although 'grain' terminology can vary between products. It typically contains 38 micrograms of T4 and 9 micrograms of T3, giving a T4:T3 ratio of approximately 4:1. Normal human thyroid secretion is closer to approximately 14:1. DTE is therefore considerably richer in T3 - and because T3 is three to four times more potent than T4, those 9 micrograms are not merely decorative passengers.

The American Thyroid Association's 2025 statement recognises that some patients choose DTE and supports continued access, provided safety issues are addressed. Its disadvantages include short-lived T3 peaks, inability to adjust T4 and T3 independently, possible overtreatment, uncertain long-term safety, manufacturing and regulatory concerns, and unsuitability during pregnancy.

Is liothyronine safe?

A large 2025 review examined clinical trials, observational studies, case reports and medicine-safety databases. When liothyronine was prescribed at medically recommended doses and appropriately monitored, the review did not find a statistically significant increase in serious adverse events, atrial fibrillation, heart failure, stroke or death.

Serious toxicity was mainly associated with excessive doses, compounding errors, unregulated products bought online, or use for weight loss or bodybuilding. Reassuring evidence for regulated treatment is not a licence for thyroid-hormone improvisation.

What happens if the dose is too high?

Excess thyroid hormone can cause:

· palpitations or a rapid heartbeat;

· tremor;

· sweating or heat intolerance;

· anxiety and difficulty sleeping;

· muscle weakness;

· loss of bone strength over time; and

· abnormal heart rhythms, including atrial fibrillation.

Long-term excessive dosing with suppressed TSH can threaten heart rhythm and bone strength.

Who might be considered for a combination-treatment trial?

Based on current specialist guidance, a trial might be discussed when:

· there is reliable evidence confirming overt primary hypothyroidism;

· significant symptoms continue despite taking levothyroxine correctly;

· the levothyroxine dose has been optimised and TSH appropriately controlled;

· enough time has been allowed to assess the optimised dose;

· the potential benefits, uncertainties and risks have been discussed;

· treatment can be prescribed and monitored by a clinician with appropriate experience; and

· there is an agreed method for deciding whether treatment has genuinely helped.

Extra caution is required for people with cardiovascular disease, heart-rhythm problems or osteoporosis risk. Liothyronine is generally unsuitable during pregnancy because an adequate maternal T4 supply is particularly important for fetal development. Pregnancy treatment should always be managed by an appropriate clinician.

How should a treatment trial be assessed?

Before combination therapy begins, the patient and clinician should agree which symptoms they are trying to improve. These might include fatigue, cognitive difficulties or reduced daily functioning. The aim is meaningful clinical improvement without evidence of excessive thyroid-hormone replacement.

If there is no clear benefit after an adequate supervised trial - often around three to six months - the additional liothyronine should normally be withdrawn in consultation with the prescribing clinician. A trial needs an exit door; otherwise it has quietly turned into a habit.

Why liothyronine and DTE are avoided during pregnancy

During pregnancy, thyroid hormone is essential for the baby's growth, particularly development of the brain and nervous system. Levothyroxine (T4) is therefore the recommended thyroid-hormone treatment during pregnancy, rather than liothyronine (T3) or desiccated thyroid extract.

Why does the developing brain need T4?

The two principal thyroid hormones are:

· T4 (thyroxine): mainly a building-block or reserve hormone that can be converted into active T3 where it is needed.

· T3 (triiodothyronine): the more active hormone, which acts directly on the body's cells.

It may seem logical to take T3 directly. Pregnancy - and especially the developing fetal brain - works differently. Early in pregnancy, the baby's thyroid gland cannot yet supply all the hormone it needs, so the baby depends heavily on T4 supplied by the mother through the placenta. T4 enters the developing brain, where specialised enzymes convert precisely the required amount into T3. This local conversion lets the fetal brain regulate its own thyroid-hormone exposure.

Why can't the baby simply use T3 from the mother?

Some maternal T3 can cross the placenta, but the placenta carefully regulates and breaks down thyroid hormones, and the fetal central nervous system is relatively impermeable to circulating T3. A good maternal T3 blood level therefore does not guarantee that enough thyroid hormone is reaching the baby's brain.

Most T3 used within the developing brain is made locally from maternal T4. In simple terms:

The mother supplies T4 -> T4 reaches the fetal brain -> the fetal brain converts it into the T3 it needs.

This is why an adequate maternal supply of T4 is so important.

What is the concern with liothyronine?

Liothyronine supplies T3 directly but does not provide the T4 that must cross the placenta and enter the fetal brain. T3 also acts quickly and can suppress the mother's TSH. Blood results may therefore appear satisfactory even when maternal T4 is too low to supply the baby adequately. The mother could have an apparently acceptable TSH or T3 result while the developing brain receives insufficient T4.

What is the concern with DTE?

DTE contains both T4 and T3, but provides a much higher proportion of T3 relative to T4 than the human thyroid normally produces. It may therefore produce relatively high T3 levels while leaving T4 lower than is desirable during pregnancy. Again, the key question is not simply the mother's measured thyroid-hormone level; it is whether enough T4 is available to cross to the baby and be converted within the developing brain.

What treatment is recommended?

Current specialist guidance recommends levothyroxine alone for treating hypothyroidism during pregnancy. Levothyroxine is identical to the T4 normally made by the thyroid gland and provides the placenta and fetal brain with the appropriate hormone from which to produce T3 as required.

If you take T3 or desiccated thyroid: if you are pregnant, planning pregnancy or undergoing fertility treatment, do not stop or alter your medication by yourself. Contact your GP, endocrinologist or pregnancy team promptly. They can arrange a safe transition to levothyroxine and monitor TSH and T4 closely before and throughout pregnancy.

With appropriate treatment and regular monitoring, most women with hypothyroidism can expect a healthy pregnancy and a healthy baby.

Anyone considering liothyronine should discuss it with an endocrinologist or another clinician experienced in thyroid-hormone treatment.

Important note

These resources and this article provide general information. Decisions about thyroid-hormone treatment should be made with an appropriately experienced clinician and based on the individual patient's diagnosis, symptoms, medical history and blood-test results. Do not start, stop or alter levothyroxine, liothyronine or desiccated thyroid treatment without medical advice, particularly during pregnancy or fertility treatment.